Blebbistatin, as David mentioned, is a myosin II inhibitor - not just non-muscle myosin II, but muscle myosins as well. It does not inhibit all myosin isoforms, however.
BDM (butanedione monoxame) is another myosin inhibitor. See more on Michael Ostap's RG page: https://www.researchgate.net/publication/10861259_23-Butanedione_monoxime_(BDM)_as_a_myosin_inhibitor
Article 2,3-Butanedione monoxime (BDM) as a myosin inhibitor
In cellular systems Blebbistatin is certainly a commonly used drug. If you do reconstituted in vitro assays you do have other choices as well. In that case you should define your problem more specifically!
A new myosin inhibitor, para-nitroblebbistatin was developed last year (Kepiro et al 2014 Angew Chem, attached). The myosin inhibitory properties are identical to those of blebbistatin; it was tested on M2 blebbing cells, HeLa cells, Dictyostelium cells, zebrafish larvae, starfish embryos, keratocytes, cardiomyocytes - not all results are published. The advantage of the derivative is that para-nitroblebbistatin is not phototoxic, not cytotoxic, not fluorescent, which make it a much more convenient and reliable inhibitor.
Several blebbistatin derivatives have now been published and some are commercially available (e.g. para-aminoblebbistatin or para-nitroblebbistatin) which target myosin 2s, including nonmuscle myosin 2. Recent reviews on the topic are: Article Targeting Myosin by Blebbistatin Derivatives: Optimization a...
and
Article The Medicinal Chemistry and Use of Myosin II Inhibitor ( S )...